Selecta Biosciences, Inc. (NASDAQ:SELB) had its target price upped by stock analysts at Canaccord Genuity from $25.00 to $30.00 in a research note issued to investors on Thursday. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity’s target price indicates a potential upside of 28.31% from the company’s previous close.

Other equities analysts also recently issued research reports about the company. Zacks Investment Research upgraded Selecta Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. ValuEngine upgraded Selecta Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, June 30th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $29.00.

Shares of Selecta Biosciences (SELB) traded up 4.94% on Thursday, reaching $23.38. The company had a trading volume of 205,192 shares. The stock has a 50-day moving average price of $19.31 and a 200-day moving average price of $19.31. Selecta Biosciences has a 12 month low of $10.27 and a 12 month high of $28.00. The stock’s market cap is $516.09 million.

Selecta Biosciences (NASDAQ:SELB) last released its quarterly earnings results on Friday, August 11th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.01. The business had revenue of $0.03 million during the quarter. Selecta Biosciences had a negative return on equity of 88.31% and a negative net margin of 1,277.76%. Analysts predict that Selecta Biosciences will post ($3.17) earnings per share for the current fiscal year.

WARNING: “Selecta Biosciences, Inc. (SELB) PT Raised to $30.00” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/12/selecta-biosciences-inc-selb-pt-raised-to-30-00.html.

In other news, CFO David Siewers sold 16,424 shares of the business’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $20.00, for a total value of $328,480.00. Following the transaction, the chief financial officer now owns 2,194 shares in the company, valued at approximately $43,880. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Amir Nashat sold 70,226 shares of the business’s stock in a transaction that occurred on Tuesday, September 26th. The stock was sold at an average price of $18.91, for a total value of $1,327,973.66. The disclosure for this sale can be found here. Insiders have sold a total of 355,658 shares of company stock valued at $6,955,732 in the last quarter. Company insiders own 41.90% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Nationwide Fund Advisors boosted its stake in shares of Selecta Biosciences by 224.5% in the 2nd quarter. Nationwide Fund Advisors now owns 6,593 shares of the company’s stock worth $131,000 after buying an additional 4,561 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Selecta Biosciences in the 1st quarter worth approximately $211,000. The Manufacturers Life Insurance Company boosted its stake in shares of Selecta Biosciences by 827.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,254 shares of the company’s stock worth $224,000 after buying an additional 10,040 shares during the last quarter. Rhumbline Advisers purchased a new position in shares of Selecta Biosciences in the 2nd quarter worth approximately $239,000. Finally, New York State Common Retirement Fund boosted its stake in shares of Selecta Biosciences by 184.0% in the 2nd quarter. New York State Common Retirement Fund now owns 12,500 shares of the company’s stock worth $248,000 after buying an additional 8,099 shares during the last quarter. Hedge funds and other institutional investors own 53.53% of the company’s stock.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.